ASP Isotopes (ASPI) EBITDA (2022 - 2026)

ASP Isotopes' EBITDA history runs 5 years deep, the most recent figure standing at -$24.9 million for Q1 2026.

• On a quarterly basis, EBITDA fell 212.98% year-over-year to -$24.9 million in Q1 2026; TTM through Mar 2026 was -$76.8 million, a 169.71% decrease from a year earlier, with the FY2025 full-year figure at -$59.9 million, down 127.32% from the prior year.
• EBITDA rose to -$24.9 million in Q1 2026 per ASPI's latest filing, from -$25.0 million in the prior quarter.
• Across five years, EBITDA topped out at -$827959.0 in Q2 2022 and bottomed at -$25.0 million in Q4 2025.
• The 5-year median for EBITDA is -$5.4 million (2024), against an average of -$7.8 million.
• Across the five-year window, EBITDA slumped 425.09% in 2023 and sank 36.75% in 2025, its largest moves.
• Year by year, EBITDA stood at -$1.5 million in 2022, then tumbled by 175.73% to -$4.0 million in 2023, then slumped by 90.1% to -$7.6 million in 2024, then sank by 227.14% to -$25.0 million in 2025, then climbed by 0.53% to -$24.9 million in 2026.
• Per Business Quant, the three latest ASPI EBITDA figures stand at -$24.9 million (Q1 2026), -$25.0 million (Q4 2025), and -$15.0 million (Q3 2025).